Prognostic value of Th1/Th2 ratio in rheumatoid arthritis

Lancet

Volumn 351, Issue 9120, 1998, Pages 1931-

  Van Der Graaff, W L ^a   Prins, A P A ^a   Dijkmans, B A C ^a   Van Lier, R A W ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; GAMMA INTERFERON; INTERLEUKIN 4;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; HELPER CELL; HUMAN; HUMAN CELL; LYMPHOCYTE SUBPOPULATION; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; RHEUMATOID ARTHRITIS;

EID: 17144443991     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(05)78615-3     Document Type: Article

References (5)

1. 1 Romagnani S. Human TH1 and TH2 subsets: doubt no more. Immunol Today 1991; 12: 256-57.
2. 2 Simon AK, Seipelt E, Sieper J. Divergent T-cell cytokine patterns in inflammatory arthritis. Proc Natl Acad Sci USA 1994; 91: 8562-66.
3. 3 Dolhain RJ, van der Heiden AN, ter Haar NT, Breedveld FC, Miltenburg AM. Shift toward T lymphocytes with a T helper 1 cytokine-secretion profile in the joints of patients with rheumatoid arthritis. Arthritis Rheum 1996; 39: 1961-69.
4. 4 Prevoo MLL, van 't Hof MA, Kuper HH, van Leeuwen MA, van de Putte LBA, van Riel PLCM. Modified disease activity scores that include twenty-eight-joint counts. Arthritis Rheum 1995; 38: 44-48.
5. 5 Rep MH, van Oosten BW, Roos MT, Ader HJ, Polman CH, van Lier RA. Treatment with depleting CD4 monoclonal antibody results in a preferential loss of circulating naive T cells but does not affect IFN-gamma secreting TH1 cells in humans. J Clin Invest 1997; 99: 2225-31.